Matthew Burke Discusses Adverse Events

First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

In this episode of "The Vitals," Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, shares her experience helping a patient reduce their opioid use through acupuncture treatments.

There continues to be an unmet need for effective and tolerable frontline treatments for patients with squamous cell carcinoma of the head and neck, according to investigators.

The American Society of Clinical Oncology (ASCO) has updated its guidelines providing recommendations for the management of cancer pain with opioids.